Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human urinary kallidinogenase + Shuxuening injection
- Development stage
- Phase 2
- Lead developer
- Guangdong Techpool Bio-pharma
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This combination therapy consists of human urinary kallidinogenase (HUK) and Shuxuening injection (SXNI), a standardized botanical extract from *Ginkgo biloba* leaves. Human urinary kallidinogenase is a glycoprotein enzyme that acts as a kininogenase, cleaving kininogen to produce kinins such as bradykinin and kallidin. These kinins activate bradykinin B2 receptors, leading to potent vasodilation, improved microcirculation, and the promotion of angiogenesis and collateral circulation in ischemic brain tissue. Shuxuening injection contains active flavonoid glycosides and terpene lactones (ginkgolides) that provide neuroprotection by antagonizing platelet-activating factor (PAF) receptors, scavenging free radicals, and inhibiting inflammatory responses. The combination is primarily investigated for the treatment of acute ischemic stroke to enhance cerebral perfusion and improve neurological recovery.
- Brand names
- Kailikang
- Other names
- HUK + SXNIhuman urinary kallidinogenase combined with Shuxuening injectionShuxuening injection + human urinary kallidinogenase
02
Targets
BDKRB1 (Bradykinin Receptor B1)Bradykinin B2 receptorKNG1 (High-molecular-weight kininogen)PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on human urinary kallidinogenase + Shuxuening injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human urinary kallidinogenase + Shuxuening injection.